Out of 28 novel drugs fda-approved to date in 2023, 6 (>20%) contain mabs (monoclonalantibodies)

Share This Post

The last one, Beyfortus (nirsevimab-alip), produced in CHOcells, represents a major breakthrough in the fight against RSV (respiratory Syncytial Virus) and is approved for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
👉 See fda press-release on July 17:

medicine at all levels: diagnostics, preventionand therapies

We, at Magellan Biologics & Consulting, proudly support R&D in this field at discovery stage by offering solutions for the fast and efficient production of proteins in CHO cells. 

🤓 Discover CHO4Tx® , our integrated system for Transient Gene Expression and our 2 options: either we run it for you or we transfer the technology and materials for you to run it in your lab.

Get updates

Subscribe To Our Newsletter

More To Explore

Interested in our products?

Drop us a line and keep in touch

Your cart is currently empty.

Welcome on board!

Subrscribe to our Newsletter
and stay updated!

Get Updates!

If you opt in above we use this information send related content